Business
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Compa...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress\n\n\n .bwlistdisc { list-style-type: disc }\n \n\n\n\n Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS), taking place Oct. 7–11, 2025, in Vienna, Austria.\n \n\n Data being presented include new analyses of data from the Phase 1b study of SAT-3247 in adults with Duchenne muscular dystrophy.\n \n\n “With our focus on targeting the underlying defect in muscle repair and regeneration, Satellos brings a unique lens to the future of Duchenne treatment,” said Frank Gleeson, co-founder and CEO of Satellos. “We’re looking forward to sharing our data from the Phase 1b study of SAT-3247 along with our clinical progress and plans for this novel investigational medicine.”\n \n\n\n Late-Breaking Poster Presentation\n \n\n\n\n\n Abstract Title:\n \n A phase 1a/b open label study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (Poster #712LBP)\n \n\n\n Presenter:\n \n Wildon Farwell, MD, MPH, Satellos Chief Medical Officer\n \n\n\n Poster session 4:\n \n Friday, Oct. 10, 3:45-4:45 p.m.\n \n\n\n\n Poster Presentation\n \n\n\n\n\n Abstract Title:\n \n Clinical progress update for SAT-3247, a first-of-its-kind, orally administered small molecule drug to address deficits in muscle repair and regeneration in Duchenne (Poster #411P)\n \n\n\n Presenter:\n \n Ryan Mitchell, PhD, Satellos SVP Medical & Scientific Affairs\n \n\n\n Poster session 1:\n \n Wednesday, Oct. 8, 2:30-3:30 p.m.\n \n\n\n Full details from the poster presentations will follow in a future press release and will be available on the\n \n Events and Presentations page\n \n of the Satellos website.\n \n\n For more information on the 30th Annual Congress of the World Muscle Society, visit\n \n www.wms2025.com\n \n .\n \n\n\n ABOUT SAT-3247\n \n\n\n SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is los...